Evidence map›Paper›PMID 34737890›Full record

ArticleFuture science OA2021

Combination of urinary fibrinogen β-chain and tyrosine-phosphorylated proteins for the detection of bladder cancer.

Giuliana Giribaldi, Claudia Filippini, Clara Viberti, Amina Khadjavi, Nicole Finesso, Daniela Ulliers, Stefano Turini, Bruno Emilio Bressan, Francesca Pecoraro, Mauro Prato and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future science OA, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 78% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Giuliana GiribaldiDepartment of Oncology, University of Turin, Turin, Italy.ORCID https://orcid.org/0000-0003-1374-1919
Claudia FilippiniDepartment of Surgical Sciences, University of Turin, Turin, Italy.
Clara VibertiDepartment of Medical Sciences, University of Turin, Turin, Italy.
Amina KhadjaviDepartment of Oncology, University of Turin, Turin, Italy.
Nicole FinessoDepartment of Oncology, University of Turin, Turin, Italy.
Daniela UlliersDepartment of Oncology, University of Turin, Turin, Italy.
Stefano TuriniDepartment of Neurosciences, University of Turin, Turin, Italy.
Bruno Emilio BressanDepartment of Oncology, University of Turin, Turin, Italy.
Francesca PecoraroDepartment of Oncology, University of Turin, Turin, Italy.
Mauro PratoDepartment of Neurosciences, University of Turin, Turin, Italy.
Alessandra AllioneDepartment of Medical Sciences, University of Turin, Turin, Italy.
Matteo De BellisDivision of Urology, Department of Surgical Sciences, AOU Città della Salute e della Scienza, Torino School of Medicine, Turin, Italy.
Gabriele MontefuscoDivision of Urology, Department of Surgical Sciences, AOU Città della Salute e della Scienza, Torino School of Medicine, Turin, Italy.
Giulia BonomessiDivision of Urology, Department of Surgical Sciences, AOU Città della Salute e della Scienza, Torino School of Medicine, Turin, Italy.
Marco AllasiaDivision of Urology, Department of Surgical Sciences, AOU Città della Salute e della Scienza, Torino School of Medicine, Turin, Italy.
Giuseppe MatulloDepartment of Medical Sciences, University of Turin, Turin, Italy.
Francesco SoriaDivision of Urology, Department of Surgical Sciences, AOU Città della Salute e della Scienza, Torino School of Medicine, Turin, Italy.
Paolo GonteroDivision of Urology, Department of Surgical Sciences, AOU Città della Salute e della Scienza, Torino School of Medicine, Turin, Italy.
University of Turin · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo evaluate the performance of urinary fibrinogen β-chain (FBC) - either alone or associated with urinary tyrosine-phosphorylated proteins (UPY) - as bladder cancer (BCa) diagnostic biomarker. MATERIALS &

methods164 subjects were tested.

resultsSignificantly different FBC and UPY levels were found between BCa patients and controls, as well as between low-grade and high-grade cancers. The diagnostic accuracy was 0.84 for FBC and 0.87 for UPY. The combination of FBC and UPY improved the accuracy to 0.91. The addition of clinical variables (age, gender, and smoking habit) to FBC and UPY into a model for BCa prediction significantly improved the accuracy to 0.99. The combination of FBC and UPY adjusted for clinical variables associates with the highest sensitivity and good specificity.

conclusionUrinary FBC and UPY could be used as biomarkers for BCa diagnosis.

Indexed as

bladder cancerfibrinogen β-chaintyrosine-phosphorylated proteinsurinary markers

Identifiers

PMID34737890
PMCPMC8558871
OpenAlexW3206985584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.